The Optimal Duration of Dual Antiplatelet Therapy After Implantation of Endeavor Stent

The Optimal Duration of Dual Antiplatelet Therapy After Implantation of Endeavor Stent in the Patients With Coronary Artery Disease (DATE Registry)

The purpose of this study to determine whether the dual antiplatelet therapy (aspirin and clopidogrel) for 3 months after coronary implantation of zotarolimus-eluting stent is safe in terms of death, myocardial infarction, or stent thrombosis.

Inclusion Criteria:

• Patients with clinically significant de novo coronary artery disease
• Stenting only with Endeavor® stents
• The sum of stent length is less than 60 mm for one lesion. The sum of stent length in multiple lesions does not matter.

Exclusion Criteria:

• Cardiogenic shock
• ST-elevation myocardial infarction within 48 hours of symptom onset
• Prior implantation of drug-eluting stents
• Left ventricular dysfunction (echocardiographic left ventricular ejection fraction < 25%)
• Stenting both branch of bifurcation lesion
• Left main trunk lesion
• Graft vessels
• Patients who have to receive clopidogrel due to other conditions
• Patients who have to receive warfarin, cilostazol or other antiplatelet therapy
• Patient with chronic renal failure (S-Cr > 2.0 mg/dl)
• Hypersensitivity to clopidogrel or aspirin
• Expectant survival less than 1 year
• Women who plan to become pregnant
• Patients with bleeding diathesis (coagulopathy, thrombocytopenia or platelet dysfunction, Gastrointestinal or genitourinary bleeding within the prior 3 months)
• Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.